STEPHEN CRUM: Open Payments
NPI 1194228551 · WOODBURN, OR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$947 in 46 payments from 14 companies in 2025. Trend: 2023 $386 · 2024 $593 · 2025 $947
Food & beverage: $947
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 11 | $232 |
| CSL Behring | 15 | $229 |
| Regeneron Healthcare Solutions, Inc. | 3 | $94 |
| Genentech USA, Inc. | 3 | $67 |
| Novartis Pharmaceuticals Corporation | 4 | $63 |
| BioCryst US Sales Co., LLC | 2 | $47 |
| Ionis Pharmaceuticals, Inc. | 1 | $38 |
| ALK-Abello, Inc | 1 | $32 |
| GlaxoSmithKline, LLC. | 1 | $31 |
| Blueprint Medicines Corporation | 1 | $29 |
Products named: DUPIXENT, Hizentra, Andembry, Xolair, Rhapsido, ORLADEYO, AYVAKIT, DAWNZERA.
Industry payments across OR — which companies pay providers there.
